Antibacterial spectrum of cefiderocol

Area of Science:

• Antimicrobial resistance
• Infectious diseases
• Pharmaceutical sciences

Background:

• Cefiderocol is a novel siderophore cephalosporin designed to overcome existing resistance mechanisms.
• It exhibits enhanced in vitro activity against extended-spectrum cephalosporins and carbapenems.
• Understanding cefiderocol's activity and resistance is crucial for combating difficult-to-treat Gram-negative infections.

Purpose of the Study:

• To evaluate the in vitro activity of cefiderocol against a range of Gram-negative bacteria.
• To investigate the mechanisms of resistance to cefiderocol.
• To compare cefiderocol's efficacy with existing cephalosporins and carbapenems.

Main Methods:

• In vitro susceptibility testing using broth microdilution (with iron-depleted media) and disk diffusion.
• Analysis of surveillance and clinical trial data against Gram-negative pathogens.
• Investigation of resistance mechanisms, including porin deficiency, efflux pumps, and specific genetic mutations.

Main Results:

• Cefiderocol demonstrated excellent in vitro activity against Gram-negative bacteria, including carbapenemase producers and non-fermenters like Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia.
• Disk diffusion showed good correlation with minimum inhibitory concentration (MIC) values.
• Few cefiderocol-resistant isolates were identified; resistance mechanisms were linked to iron transporter gene mutations, AmpC mutations, and specific beta-lactamases (KPC-variants, PER, BEL, NDM, SPM).

Conclusions:

• Cefiderocol is a promising therapeutic option against challenging Gram-negative infections, including those caused by carbapenem-resistant strains.
• Resistance mechanisms are primarily associated with alterations in iron uptake pathways and specific beta-lactamases, rather than porin or efflux pump alterations.
• Further research into cefiderocol resistance is warranted to guide clinical use and antimicrobial stewardship.